| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/27/2011 | US20110020222 Modified antibodies and methods of use |
| 01/27/2011 | US20110020220 Humanized antibodies against the beta-amyloid peptide |
| 01/27/2011 | US20110020219 Anti-human tenascin monoclonal antibody |
| 01/27/2011 | CA2768547A1 E-polylysine conjugates and use thereof |
| 01/26/2011 | EP2278007A1 Conserved neisserial antigens |
| 01/26/2011 | EP2277553A1 Preparations for time-limited marking of biopsy sites |
| 01/26/2011 | EP2277548A2 Magnetic nanoparticles linked to a ligand |
| 01/26/2011 | EP2277547A1 Epsilon-polylysine conjugates and their utilisation |
| 01/26/2011 | EP2277544A1 Biocompatible magnetic nano-clusters containing iron oxide respectively iron oxide - boron with primary use in magnetic drug targeting and boron neutron capture therapy |
| 01/26/2011 | EP2277507A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/26/2011 | EP2276475A1 Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules |
| 01/26/2011 | EP1989179B1 Contrast agents |
| 01/26/2011 | EP1551478B1 Threaded syringe with quick stop |
| 01/26/2011 | CN1795929B Method for generating model of mice in male sterility |
| 01/26/2011 | CN101955981A Novel target for developing medicaments for treating diabetes, obesity and cardiovascular diseases and biological characteristics thereof |
| 01/26/2011 | CN101954096A Multifunctional ultrasound contrast agent and preparation method thereof |
| 01/26/2011 | CN101953795A Drug delivery nanodevice, its preparation method and uses thereof |
| 01/26/2011 | CN101259082B Root canal anti-inflammation developing agent and preparation thereof |
| 01/25/2011 | US7877133 Marker or filler forming fluid |
| 01/25/2011 | US7875454 Exposing the tissue to ionizing radiation; administering a delivery vehicle, platelets; leukocytes; proteins or peptides of the active agent; treating neoplasms, cancers, tumors |
| 01/25/2011 | US7875259 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 01/25/2011 | CA2453278C Diagnostic agents for pancreatic exocrine function |
| 01/25/2011 | CA2430339C A process for the preparation of iopamidol and the new intermediates therein |
| 01/25/2011 | CA2333833C Specific binding molecules for scintigraphy,conjugates containing them and therapeutic method for treatment of angiogenesis |
| 01/21/2011 | CA2710635A1 Stabilizing aqueous solution of iodine chloride by adding sodium chloride |
| 01/21/2011 | CA2710618A1 Synthesis of iodixanol in methanol |
| 01/21/2011 | CA2710598A1 Synthesis of iodixanol in water |
| 01/21/2011 | CA2710582A1 Decolorizing contrast media intermediates |
| 01/21/2011 | CA2710573A1 A continuous process of preparing intermediate for non-ionic x-ray contrast agents |
| 01/21/2011 | CA2710570A1 Acetylation using reduced concentration of acetic acid anhydride for synthesizing non-ionic x-ray contrast agents |
| 01/21/2011 | CA2710108A1 Process for isolating iodixanol from an aqueous solution |
| 01/21/2011 | CA2710107A1 Recovering unreacted intermediate from desalinated and desolventized dimerisation reaction mixture by ultrafiltration |
| 01/21/2011 | CA2710105A1 Obtaining free iodine in preparation of aqueous iodine chloride by adding potassium iodide |
| 01/21/2011 | CA2710102A1 Improvements in crystallization of an intermediate for synthesizing non-ionic x-ray contrast agents |
| 01/21/2011 | CA2710090A1 Acetylation using reduced volume of acetic acid anhydride for synthesizing non-ionic x-ray contrast agents |
| 01/20/2011 | WO2011008996A2 Peptides whose uptake in cells is controllable |
| 01/20/2011 | WO2011008992A2 Peptides whose uptake in cells is controllable |
| 01/20/2011 | WO2011008823A2 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier |
| 01/20/2011 | WO2010138899A3 Trimethylamine-containing compounds for diagnosis and prediction of disease |
| 01/20/2011 | WO2010125068A3 Labeled molecular imaging agents, methods of making and methods of use |
| 01/20/2011 | US20110016537 Cellular model of tauopathies for lead identification and drug discovery |
| 01/20/2011 | US20110014129 Magnetic microstructures for magnetic resonance imaging |
| 01/20/2011 | US20110014128 Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same |
| 01/20/2011 | US20110014127 Methods for measuring a patient response upon administration of a drug and compositions thereof |
| 01/20/2011 | US20110014126 Use of vitamin d receptor agonists and precursors to treat fibrosis |
| 01/20/2011 | US20110014125 Protease assay |
| 01/20/2011 | US20110014124 Targeted atherosclerosis treatment |
| 01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
| 01/20/2011 | US20110014122 Novel anti-igf-ir and/or anti-insulin/igf-i hybrid receptors antibodies and uses thereof |
| 01/20/2011 | US20110014121 Modulators of cxcr7 |
| 01/20/2011 | US20110014117 Anti-igf1r |
| 01/20/2011 | CA2770980A1 Peptides whose uptake in cells is controllable |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275449A1 Antibodies that immunospecifically bind to blys |
| 01/19/2011 | EP2275446A2 Antibodies to insulin-like growth factor I receptor |
| 01/19/2011 | EP2275416A1 Biologically active methylene blue derivatives |
| 01/19/2011 | EP2275144A2 Medium for contrast enhancement or convenience for ultrasonic, endoscopic and other medical examinations |
| 01/19/2011 | EP2275094A2 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| 01/19/2011 | EP2274019A2 Dye solution |
| 01/19/2011 | EP2274011A2 An antibody bound synthetic vesicle containing active agent molecules |
| 01/19/2011 | EP2273870A1 Animal model for diabetes |
| 01/19/2011 | EP2068938B1 Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib |
| 01/19/2011 | CN101952433A PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
| 01/19/2011 | CN101952369A Optical imaging agents |
| 01/19/2011 | CN101951964A Imaging method |
| 01/19/2011 | CN101951963A MR imaging agent, imaging medium and methods of imaging wherein such an imaging medium is used |
| 01/19/2011 | CN101951962A Fluorescent nanoparticle compositions, methods, and devices |
| 01/19/2011 | CN101951961A Composition and method for detection of demineralisation |
| 01/19/2011 | CN101951953A Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient |
| 01/19/2011 | CN101948921A Application of NOB1 gene in treating brain glioma disease |
| 01/19/2011 | CN101948694A Rare earth upconversion nano crystal/silver difunctional composite nano material, preparation method thereof and application thereof in cancer detection and treatment |
| 01/19/2011 | CN101948488A Ruthenium-selenium coordination compound and application thereof in preparing fluorescent probe and antineoplastic medicine |
| 01/19/2011 | CN101948380A Perturbed membrane-binding compounds and methods of using the same |
| 01/19/2011 | CN101120921B Target preparation consisting of liposome and nucleic acid coating contrast agent |
| 01/19/2011 | CN101002950B Magnetic resonace imaging contrast medium with glycyrrhizic acid as carrier |
| 01/18/2011 | US7871620 Immunoliposomes that optimize internationalization into target cells |
| 01/18/2011 | US7871597 Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis |
| 01/18/2011 | US7871596 Higher fatty acid triester compound having diethylenetriamine-type metal chelate structure |
| 01/13/2011 | WO2011005609A2 Imaging gastrointestinal volumes and motility |
| 01/13/2011 | WO2011005322A2 N-alkoxyamide conjugates as imaging agents |
| 01/13/2011 | WO2011004049A1 Method for identifying immunomodulating compounds for the skin |
| 01/13/2011 | WO2011003996A1 In vivo tumor vasculature imaging |
| 01/13/2011 | WO2011003902A2 Multimodal visible polymer embolization material |
| 01/13/2011 | WO2011003818A2 Diagnostic method |
| 01/13/2011 | WO2011003357A1 Nuclear magnetic resonance contrast agent for liver or spleen and preparation method thereof |
| 01/13/2011 | WO2010135431A3 Compositions, devices, and methods related to prostate-specific membrane antigen |
| 01/13/2011 | WO2010133941A3 New hybrid particles and their use in diagnostics and therapy |
| 01/13/2011 | WO2010111219A3 Site localization and methods for monitoring treatment of disturbed blood vessels |
| 01/13/2011 | WO2010066843A3 Biomolecule complexes as contrast agents in positron emission tomography (pet) based methods for the assessment of organ function |
| 01/13/2011 | US20110008263 Contrast agents |
| 01/13/2011 | US20110008262 Drug delivery system targeting to estrogen receptor over-expressed cells |
| 01/13/2011 | US20110008261 Method to produce hyperpolarised amino acids and aminosulphonic acids |
| 01/13/2011 | US20110008260 Use of Nanocrystals for Drug Delivery from a Balloon |
| 01/13/2011 | US20110008259 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/13/2011 | US20110008258 Methods relating to breathing disorders |
| 01/13/2011 | US20110008257 Inhibitors of bruton's tyrosine kinase |
| 01/13/2011 | US20110008256 Monoclonal antibodies that bind or neutralize dengue virus |
| 01/13/2011 | US20110008255 Beta-amyloid pet imaging agents |
| 01/13/2011 | US20110008251 Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses |
| 01/13/2011 | CA2803520A1 N-alkoxyamide conjugates as imaging agents |